Mechanisms of Retinal Ganglion Cell Death in Glaucoma
Principal Investigator
Neeraj Agarwal, PhD
University of North Texas Health Science Center
Fort Worth, TX, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$24,203
Active Dates
April 01, 1998 - March 31, 1999
Grant ID
G1998422
Summary
One of the causative events that ultimately leads to blindness in glaucoma is the destruction of ganglion cells in the retina by a process known as apoptosis, or programmed cell death. In order to study how these ganglion cells undergo cell death, we are in the process of establishing a culture of ganglion cells. It is believed that one reason for the apoptosis of ganglion cells could be due to deprivation of oxygen and nutrient supply to these cells. We would like to mimic these conditions in vitro (outside the living organism), by limiting the oxygen and glucose supply to these cultured cells. We would like to study the expression of some “cell saver” genes like Bcl-2 and others like Bax and ICE, which facilitate cell death, under these experimental conditions. We would also like to study, if we could protect the cells from apoptosis by pretreatment with well known antioxidants and ICE inhibitors. These studies could provide very important leads to save the ganglion cells from a pathway leading to its cell death.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet